- Trial phase
- Phase 3 (completed pivotal trial)
- Time to market
- Regulatory submission to the FDA is expected imminently (H2 2026). If filed, a standard FDA review would take approximately 6-12 months, suggesting a potential approval decision in the second half of 2027 at the earliest.
- Why 4/10
- The next hard catalyst is the regulatory submission to the FDA, which Novo Nordisk has said it plans to make in the second half of 2026 (now imminent as of November 2026). However, no PDUFA date has been set, and the drug is a very small part of Novo Nordisk's massive GLP-1-dominated business, so impactScore is capped at 4.
Watch for Novo Nordisk's regulatory submission of etavopivat to the FDA, expected in the second half of 2026 (imminent). If filed, a PDUFA date would be set roughly 6-12 months later. The key competitive dynamic is Agios' mitapivat, which has a PDUFA date of February 1, 2027 for the same sickle cell indication. Etavopivat's once-daily dosing could be a differentiator versus mitapivat's twice-daily regimen.
Price Chart
Executive Summary
Etavopivat (formerly FT-4202) is Novo Nordisk's investigational once-daily oral pill for sickle cell disease, acquired through the $1.1 billion purchase of Forma Therapeutics in 2022. In April 2026, the pivotal Phase 3 HIBISCUS trial met both co-primary endpoints: a 27% reduction in painful vaso-occlusive crisis events and a 48.7% hemoglobin response rate at 24 weeks (vs 7.2% on placebo). Novo Nordisk plans to submit for first regulatory approval in the second half of 2026, with filings reportedly being prepared as of early November 2026. The drug competes directly with Agios' mitapivat, which has a PDUFA date of February 1, 2027 for the same indication. Etavopivat is a small part of Novo Nordisk's massive, GLP-1-dominated business, so even a successful approval would have limited impact on NVO's share price.
How It Works
Etavopivat is an oral pill taken once daily that activates an enzyme called pyruvate kinase-R (PKR) inside red blood cells. This activation boosts the cells' energy (ATP) and lowers a substance called 2,3-DPG, which together make the red blood cells healthier and less likely to deform into the sickle shape that causes painful blockages in blood vessels. It is designed to treat sickle cell disease, an inherited blood disorder where misshapen red blood cells clog vessels, causing severe pain episodes and organ damage.
Trial Status
The pivotal Phase 2/3 HIBISCUS trial (NCT04624659) met both co-primary endpoints in April 2026. A Phase 3b trial (HIBISCUS2) and an open-label extension (FLORAL, NCT06609226) are ongoing. A Phase 2 study in thalassemia (GLADIOLUS, NCT04987489) is ongoing. A Phase 2 study in myelodysplastic syndromes was terminated.
The Two-Sided Case
Upcoming Catalysts
- Regulatory submission to the FDA (expected H2 2026, imminent)
- Detailed Phase 3 HIBISCUS results presentation at a scientific conference
- Potential PDUFA date assignment following FDA submission
- HIBISCUS2 (Phase 3b) topline readout
- FLORAL open-label extension safety data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report